February 2026 Options Now Available For Invesco (IVZ)

The piece outlines two option strategies on Invesco Ltd (IVZ, current price $26.84): selling a $24 put (bid $0.15) which would set an effective cost basis of $23.85 and is ~11% out-of-the-money with a 71% chance to expire worthless, yielding 0.62% (3.56% annualized) if it does; and selling a $27 covered call (bid $0.10) while holding stock, a ~1% OTM strike with a 48% chance to expire worthless, providing a 0.37% boost (2.12% annualized) and 0.97% total return if called at Feb 2026. Implied volatilities are 61% for the put and 41% for the call versus a 12-month trailing volatility of 40%; the article frames these as trade ideas and tracks probability and yield metrics over time.

Analysis

Market structure: Short-dated option sellers and retail income strategies are the direct beneficiaries — selling the IVZ Feb‑2026 $24 put nets a 0.62% cash yield (3.56% annualized) with a 71% modeled OTM survival probability, while covered‑call sellers can pocket 0.37% (2.12% annualized). Issuers (Invesco) and competing asset managers are largely neutral here; brokers/venues capture transaction flow and volatility risk‑premium (put IV 61% > realized 40%) implying sellers are being paid extra for tail risk.

Risk assessment: Key tail risks are a sector‑wide AUM shock or macro equity drawdown (>20% SPX drop) that would breach the $24 strike and turn premium into realized losses; regulatory actions or large client redemptions at Invesco could compress metadata and spike IV above 80% rapidly. Timewise, option decay works in weeks→months (Feb 2026), but fundamental re‑rating of IVZ is a quarters→years story tied to AUM and fee pressure.

Trade implications: Tactical defined‑risk option sells (bull put spreads) are preferred to naked puts given elevated put IV; prefer selling premium when IV>55% and buying back when IV mean‑reverts toward 40%. For directional exposure, a cash+covered‑call package (buy IVZ at <=$26, sell $27 Feb‑2026) caps upside but generates ~1% to expiry; scale positions to 1–3% portfolio and use hard stops if IVZ < $22.5 or market‑wide volatility spikes.

Contrarian angles: Consensus treats IVZ option premium as small income play; it understates assignment liquidity/operational risk if forced to buy shares in a fast downtrend. The mispricing signal — 61% put IV vs 40% realized — is actionable but not free lunch: historical parallels (2020 drawdown) show option sellers can be wiped out in systemic events, so defined‑risk constructions outperform naked exposure.

Key Decisions for Investors

• Sell-to-open IVZ Feb‑2026 $24 put (collect $0.15) sized to 1–1.5% of portfolio only if comfortable owning IVZ at $23.85; set buy-to-close if IVZ ≤ $22.50 or unrealized mark-to-market loss >3× premium, and trim if implied vol rises >+20 pts.
• Prefer defined-risk trade: sell IVZ Feb‑2026 $24 / buy $22 bull put spread (width $2) sized 2% portfolio — max loss $1 per spread — deploy when IV>55% and buy-to-close if IV drops below 45% or IVZ > $27.
• If seeking equity exposure, initiate purchase of IVZ at ≤ $26 and sell Feb‑2026 $27 covered calls (target 1% yield to expiry), weight 1–3% portfolio, roll calls if IVZ rallies >10% or close position if IVZ < $24.50.
• Hedge systemic tail risk: allocate 0.5–1% portfolio to 3‑month SPX put spread (e.g., 10%/20% OTM) or long VIX calls to protect against a >15% market drawdown that would invalidate short‑premium strategies within 30–90 days.